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Identity 
Other names: MED1 
HGNC (Hugo): MBD4 
Location: 3q21.3 
Local order: Between the C3orf25 and IFT122 genes. 
Note: Homologous to MeCP2 gene. 
DNA/RNA 
Description 
MBD4 (NM_003925) is a gene of 9060 bp coded by 8 
exons from 129158852 to 129149792 according to 
GRCh37 human genome assembly v37 by IGB 
browser. 
Transcription 
The transcript encoded by NM_003925.1, mRNA 
length of 2470 bp. 
Protein 
Note 
MBD4 has two significant domains identified by 
homology and functional analysis: a highly conserved 
glycosylase domain (60% conservation between 
species) at the C-terminus, and a less well conserved 
methyl-CpG binding (MBD) domain (37% 
conservation between species) at the N-terminus 
(Bellacosa et al., 1999; Hendrich and Bird, 1998; Meng 
et al., 2011). The domain structure of MBD4 indicates 
that the gene could have been  
formed from the fusion of a glycosylase motif with a 
methyl-CpG binding domain (Hendrich and Tweedie, 
2003). The N-terminal MBD domain of MBD4 is able 
to discriminate between methylated and unmethylated 
double stranded DNA (Hendrich and Bird, 1998). The 
N-terminal glycosylase domain of MBD4 was shown in 
vitro to recognise and repair the mismatched products 
from deamination including Thymine and Uracil 
(Hendrich et al., 1999; Wong et al., 2002), thus it has 
been proposed to take part in active demethylation. The 
methyl-CpG binding domain of MBD4 binds 
preferentially to m5CpG x TpG mismatches - the 
primary product of deamination at methyl-CpG. 
It has been proposed that MBD4 proteins arose as a 
fusion protein between MBD and glycosylase domain 
ancestors in the vertebrate lineage, and MBD2/3 
represents the ancestral methyl-CpG binding protein 
(Hendrich and Tweedie, 2003). Interestingly, a 
prototypical MBD4 protein and its putative ancestor 
MBD2/3 were identified outside vertebrates in the 
cephalochordate amphioxus (Branchiostoma floridae) 
(Albalat, 2008), in addition a putative MBD4 gene was 
predicted in the Ciona intestinalis genome, but this 
lacks an MBD domain. The finding of a putative 
MBD4 protein in this invertebrate-vertebrate transition 
model organism pushes back the origin of MBD4 
proteins in evolutionary time, and argues against the 
fusion hypothesis of origin of MBD4 proteins (Albalat, 
2008). The MBD domain of MBD4 is most similar to 
that of MeCP2 in primary sequence (Ballestar and 
Wolffe, 2001; Hendrich and Bird, 1998). 










The longest Human MBD4 protein has 580 amino 
acids, at approximately 66 kDa. 
Expression 
MBD4 expressed in all tissues tested with highest 
levels in Tonsil and Early Erythroid (CD71+) 
(BioGPS). 
Localisation 
MBD4 is a nuclear protein. Overexpressed MBD4-GFP 
co-localises to heterochromatin sites in mouse cells and 
can recruit partner proteins e.g. MLH1 (Hendrich and 
Bird, 1998; Ruzov et al., 2009). 
Function 
MBD4 is a methyl-CpG binding glycosylase (Bellacosa 
et al., 1999) that can excise and repair both C-T and C-
U mutations at methylated and non-methylated CpGs 
via its glycosylase domain and adjacent binding site 
(Hendrich et al., 1999). Novel interacting partners of 
MBD4 include the mis-match repair (MMR) protein 
MLH1 (Bellacosa et al., 1999) and Fas-associated 
death domain (FADD) protein (Screaton et al., 2003), 
suggesting a potential link between genome 
surveillance and apoptosis. Consistent with these 
observations, reduced apoptosis occurs in the small 
intestine of mbd4-/- mice in response to a variety of 
DNA-damaging agents (Cortellino et al., 2003), and 
increased gastrointestinal tumorigenicity was observed 
for mbd4-/- mice on a tumor-susceptible Apc min 
background (Millar et al., 2002). Although Mbd4 
inactivation did not increase mini-satellite instability 
(MSI) in the mouse genome, it did result in a 2- to 3-
fold increase in C-to-T transition mutations at CpG 
sequences in splenocytes and epithelial cells of the 
small intestinal mucosa. The change in the 
gastrointestinal cancer phenotype was associated with 
an increase in somatic C-to-T mutations at CpG sites 
within the coding region of the wild-type Apc allele. 
These studies indicate that Mbd4 inactivation may alter 
the mutation spectrum in cancer cells and modify the 
cancer predisposition phenotype. 
MBD4 can repress several methylated reporter genes 
(Fukushige et al., 2006; Kondo et al., 2005). However 
the global genomic targets of MBD4 have not been 
characterised. MBD4 knock out mice are viable and 
fertile, and show only mild physiological defects  
(Millar et al., 2002). However, morpholino knock-
down of xMbd4 in Xenopus laevis shows serious 
developmental defects and fails to develop to a tadpole. 
Re-introduction of mouse Mbd4 mRNA can rescue the 
phenotype (Ruzov et al., 2009). There is increased C-T 
mutation rate observed in the Mbd4 knock out mice as 
a consequence of reduced glycosylase activity (Millar 
et al., 2002). 
MBD4 can interact directly with both DNMT1 and 
MLH1 leading to recruitment of all three components 
at sites of DNA damage (Ruzov et al., 2009). The co-
localization of DNMT1, MBD4 and MLH1 suggests 
that they may participate in a cellular checkpoint that 
monitors potential DNA hypomethylation events by 
detecting the presence or absence of the maintenance 
methyltransferase Dnmt1, perhaps at or adjacent to the 
replication fork. The recruitment of these components 
in response to localized DNA damage suggests that can 
have a role in the cellular decision whether to repair the 
lesion or activate apoptosis (Ruzov et al., 2009). 
Decreases in DNMT1 protein levels in ES cells and 
normal differentiated human cells can result in 
mismatch repair (MMR) defects (Guo et al., 2004; Kim 
et al., 2004; Loughery et al., 2011; Wang and James 
Shen, 2004) In the hTERT-1604 fibroblast cell line, a 
normal diploid cell line immortalised by telomerase 
over-expression, depletion of DNMT1 is sufficient to 
cause MMR defects and increased mutation rates at a 
CA17 microsatellite. This is associated with decreases 
in MMR protein levels, including MBD4: following 
activation of the DNA damage response (DDR). 
Blocking the DDR, and in particular PARP over-
activation, also increases survival of the DNMT1 
knockdowns (Loughery et al., 2011). 
zMbd4 has been proposed to be a candidate protein that 
is involved in DNA demethylation activity in Zebrafish 
(Rai et al., 2008). Rai and colleagues showed MBD4 
removes G:T mismatch-specific thymines, resulting 
from deamination of 5-methylcytosine (5-meC) via 
cytidine deaminase family members (Activation 
Induced deaminase (AID) and Apolipo-protein B RNA-
editing catalytic component (Apobec)). Interestingly, 
deamination activity by AID/Apobec did not occur 
unless MBD4 and/or other possible factor are present 
and/or activated, and a catalytically inactive hMBD4 
derivative (D560A) stabilized the putative G:T 
intermediate and prevented rapid thymine removal (Rai 
et al., 2008). MBD4 was also reported  










to interact with Xenopus DNMT1 to promote p53 
dependent apoptosis (Ruzov et al., 2009), and 
DNMT3b, which was is proposed to methylate cytosine 
and to deaminate 5-meC, relying on an inefficient 
deaminase activity (Kangaspeska et al., 2008; Metivier 
et al., 2008). Recent studies in mice have implicated 
thymine DNA-glycosylase (TDG) in active DNA 
demethylation, TDG interacts with the deaminase AID 
and the damage response protein GADD45a. These 
findings suggest a two-step mechanism for DNA 
demethylation in mammals, whereby 5-methylcytosine 
and 5-hydroxymethylcytosine are first deaminated by 
AID to thymine and 5-hydroxymethyluracil, 
respectively, followed by TDG-mediated thymine and 
5-hydroxymethyluracil excision repair (Cortazar et al., 
2011; Cortellino et al., 2011). It is possible that MBD4 
may make a contribution to this process. 
Homology 
MBD4 is a member of the methyl-CpG binding 
proteins that contain the MBD motif; the other 
members in the family are MeCp2, MBD1, MBD2, 
MBD3 (Hendrich and Bird, 1998; Klose and Bird, 
2006). The protein with closest MBD homology to 
MBD4 is MeCP2. 
Mutations 
Note 
A C-terminal truncation of MBD4 containing its MBD 
domain was detected in the HCA7 cell line (colon 
cancer cell line) (Bader et al., 1999). Frequent MBD4 
mutations were reported in MSI tumours in sporadic 
colon cancers and in hereditary non-polyposis 
colorectal cancer (HNPCC) tumours. The frequency of 
MBD4 mutations was correlated with MSH2/MLH1 
germline mutations (Riccio et al., 1999). In humans, 
frame-shift mutation of MBD4 occurs in up to 43% of 
microsatellite unstable colon cancers. Recombinant  
truncated MBD4 (MBD4tru) inhibits glycosylase 
activities of normal MBD4 or Uracil DNA glycosylase 
in cell-free assays as a dominant negative effect. Over-
expression of MBD4tru in Big Blue (lacI)-transfected, 
MSI human colorectal carcinoma cells doubled the 
mutation frequency, indicating that the modest 
dominant negative effect on DNA repair can occur in 
living cells in short-term experiments. Intriguingly, the 
whole mutation spectrum was increased, not only at 
CpG sites, suggesting that truncated MBD4 has a more 
widespread effect on genomic stability. This 
demonstration of a dominant negative effect may be of 
significance in tumour progression and acquisition of 





A reduced apoptotic response occurs in the small 
intestine of mbd4-/- mice in response to a variety of 
DNA-damaging agents, and increased tumorigenicity 
was observed on a background of mbd4-/- with the 
tumor-susceptible Apc min background in mice (Millar 
et al., 2002; Sansom et al., 2003; Wong et al., 2002). A 
frame-shift in a polyadenine tract due to an MMR 
defective background resulted in a mutated form of 
MBD4 that occurs naturally in human colon cancers 
(Abdel-Rahman et al., 2008). This leads to a premature 
truncation of the MBD4 protein, which has an intact 
MBD domain but lacks of the whole glycosylase 
domain. It has been suggested that this truncated form 
of MBD4 acts in a dominant negative way, 
competitively inhibiting normal glycosylase activity of 
wild type MBD4, and increases mutation frequency 
when overexpressed in cells (Bader et al., 2007). The 
frameshift mutations in MBD4 appear to be selected for 
in MSI tumour cells, as similar coding polyadenine 






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10)  1044 
repeats in other tested genes are rarely altered in this 
panel of 56 primary MSI tumours (Riccio et al., 1999). 
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